{"meta":{"query_hash":"b86de379d351","filters":{"venue":"Journal of Current Oncology"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b86de379d351","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Current+Oncology"},"results":[{"id":"W2889732036","doi":"10.4103/jco.jco_3_18","title":"Response to osimertinib in EGF816-resistant T790M-mutated lung cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; T790M; Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Adenocarcinoma; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Cancer research; Gefitinib; Cancer; Receptor; Erlotinib","score_opus":0.04712176482318364,"score_gpt":0.4887936186369286,"score_spread":0.44167185381374496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889732036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949604,0.0015819569,0.000298084,0.000710722,0.00004912847,0.000038995393,0.00007044795,0.000024150524,0.0022661402],"genre_scores_gemma":[0.9987557,0.0002973277,0.00009104332,0.00021919596,0.000026586316,0.0000037943946,0.00007957557,0.000003230516,0.00052358245],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99992454,0.00001149704,0.0000079745205,0.000015644015,0.000013532968,0.000026784524],"domain_scores_gemma":[0.9998497,0.00003703573,0.000018906947,0.000007745239,0.0000115456105,0.00007500699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014225446,0.00019666435,0.00040647466,0.00019232374,0.00030260015,0.00024080837,0.00016706868,0.0005659957,0.0004528359],"category_scores_gemma":[0.00036859175,0.00007565473,0.00025428753,0.00014348915,0.00017022701,0.00015475422,0.000112482565,0.00075522927,0.00015689287],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00940142,0.0019882875,0.09699966,0.00027960667,0.00017950479,0.63662964,0.0007818891,0.002610832,0.108989805,0.00059808063,0.0034315954,0.13810964],"study_design_scores_gemma":[0.00084985147,0.033098113,0.2825684,0.00008913551,0.00033880697,0.60696,0.00047278224,0.009906445,0.050624926,0.0007778286,0.01423807,0.000075631375],"about_ca_topic_score_codex":0.00071290135,"about_ca_topic_score_gemma":0.00208882,"teacher_disagreement_score":0.00071290135,"about_ca_system_score_codex":0.00047482055,"about_ca_system_score_gemma":0.00015858661,"threshold_uncertainty_score":0.0034450889},"labels":[],"label_agreement":null}]}